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Amoxicillin is associated with a lower risk of further antibiotic 
prescriptions for lower respiratory tract infections in primary care – A 
database analysis spanning over 30 years 
Antibiotic prescriptions for lower respiratory tract infections occur commonly in 
primary care but there is uncertainty about the most effective initial treatment 
strategy. Both increasing antimicrobial resistance and awareness of preventable 
harm from medicines make resolving this uncertainty a priority.  Pragmatic, real-
life epidemiological investigations are needed to inform future interventional 
studies.  
In this cross-sectional database study we analysed antibiotic prescriptions for non-
pneumonic, lower respiratory tract infections (LRTI) in primary care as captured 
in the Optimum Care Database from 1984 to 2017. The primary outcome was a 
second antibiotic prescription for a LRTI code within 14 days of index prescription, 
the secondary outcome further antibiotic prescription for any indication. Only 
individuals without chronic respiratory diseases were included. We conducted 
univariable analysis to identify factors associated with repeat prescriptions and 
generate hypotheses for forthcoming projects. 
We analysed 367,188 index prescriptions for LRTI. Amoxicillin was the 
commonest used index drug (65.1%). In 6% a second antibiotic course coded for a 
further LRTI was prescribed (11.2% without this coding restriction). Further 
antibiotic prescriptions for LRTI were significantly associated with older age, 
previous smoking, seven day index courses and not using amoxicillin initially. The 
largest effect size was seen when amoxicillin was not used as index drug (odds 
ratio (OR) 1.15, p<0.001). This would support current prescribing practice for 
amoxicillin as index drug in those without respiratory disease. Prospective studies 
are needed to explore the observed differences.  
Keywords: antibiotics; lower respiratory tract infections; primary care; 
amoxicillin; treatment failure; database 
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 Introduction 
Lower respiratory tract infections (LRTI) are the commonest reason for antibiotic 
prescriptions in primary care across Europe and the probability of antibiotic prescription 
for coughs and colds by general practitioners in the United Kingdom (UK) increased by 
40 % between 1999 and 2011 [1,2]. It is presumed that there are variations in prescribing 
practice but unclear whether these result in different patient outcomes. 
Primary care is an ideal target for optimising antibiotic therapy since 74 % of all 
UK antibiotics are prescribed here [3]. The risks of rising antimicrobial resistance and 
adverse effects, including infective diarrhoea, must be balanced with treatment failure [4–
7].  
Since real-life experiences should inform real-life decision making, we undertook 
this retrospective observational investigation of antibiotic prescriptions in non-
pneumonic LRTI and their outcomes from 1984 to 2017. We described prescribing 
practice and investigated factors associated with repeat prescriptions with the aim to 
identify areas for further investigations.  
 
Methods 
We carried out a cross-sectional database study drawing on retrospective, electronic 
medical records from the Optimum Patient Care Research Database (OPCRD). We 
included all subjects older than 15 years who received at least one antibiotic prescription 
for LRTI from 27th April 1984 to 5th January 2017. Primary outcome was a new antibiotic 
prescription for a LRTI READ code within 14 days of initial prescription. Secondary 
outcome was an antibiotic prescription for any indication within 14 days of index 
prescription. We excluded cases with coded diagnoses of pneumonia, chronic respiratory 
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conditions (e.g. asthma, chronic obstructive pulmonary disease (COPD)) and those whose 
index antibiotic course was longer than 28 days.  
The OPCRD comprised data extracted through the Optimum Patient Care (OPC) 
Clinical Service Evaluation (http://optimumpatientcare.org/opcrd/). The OPCRD is a 
research-quality primary care database with a focus on respiratory diseases. It contained 
anonymised, routinely recorded patient data from over 525 UK general practices. The 
OPCRD was approved by the Trent Multi-Centre Research Ethics Committee for clinical 
research use. The study protocol was approved by the OPCRD’s Anonymised Data Ethics 
Protocols and Transparency Committee.  
Data was analysed using SPSS version 22 (IBM). Univariable analysis was 
carried out for gender, age, body mass index (BMI), smoking status, index antibiotic drug 
and index duration. Statistically significant results were defined as p < 0.05, 95% 
confidence intervals were given where appropriate. Summary statistics, odds ratios, Chi-
squared and student T-tests were presented as appropriate for each variable based on type 
and distribution of data. Subgroup analysis was carried out for cases with more than one 
index prescription and cases from 1st January 2011 to 5th January 2017 to establish if the 
observed effects were maintained in current antibiotic prescribing practice.  
 
Results 
There were 1,549,402 antibiotic prescriptions in the OPCRD from 1984-2017; of these 
753,885 were for “simple” LRTI (ie no underlying asthma, COPD or other chronic lung 
disease) in patients over 15 years. “Chest infection not otherwise specified”, “bronchitis” 
and “lower respiratory tract infections” were the commonest codes for LRTI (67.5%, 
21.7%, 10.2% respectively). We analysed the 367,188 cases (51%) for which an index 
duration was clearly documented (see supplementary figure).  
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 Of the total eligible 367,188 index prescriptions, 58.9% occurred in female 
patients. Mean age was 55.4 years, range 16-106 years. Mean BMI was 28.1 ± 6.1 
(standard deviation, SD). 35.4% were non-smokers, 27% current smokers and 28.9% 
were ex-smokers (missing smoking status in 8.7%). Most prescriptions occurred from 
2006-2010 (35.3%). Most patients received only one index prescription (59.3%), with 
20.4% having two and 20.3% three or more separate index prescriptions. The commonest 
index duration was 7 days (74.1%), followed by 5 or 6 days (22.7%). Amoxicillin was 
the index antibiotic prescribed most frequently (65.1%), clarithromycin and erythromycin 
were the next most frequent (9.1% and 7.4% respectively).  548 cases received 2 further 
antibiotic courses within 14 days of the index prescription – these were excluded from 
further analysis. 
 
Further antibiotic prescriptions for LRTI 
41,227 cases had a second antibiotic prescription within 14 days of the index prescription 
(11.2%). More than half of the additional antibiotic prescriptions were coded for another 
LRTI (54.8%, 22,176 of 41,227). Most of the 22,176 second prescriptions for another 
LRTI code were for 7 days (75.2%). Clarithromycin, amoxicillin and doxycyline were 
the most commonly used second line antibiotics (23.3%, 15.5% and 15.1% respectively).  
Those receiving further antibiotics for LRTI were significantly older (mean 57.5 
versus 54.1 years, mean difference -3.4 (MD), 95% CI -3.6 - -3.1, p<0.001) than those 
not receiving antibiotics (see table 1). Current smokers had a significantly reduced risk 
of repeat antibiotic prescription for LRTI compared to non-smokers (OR 0.78, 95% CI 
0.78-0.81, p<0.001). Ex-smokers were more likely to receive repeat antibiotics than 
non-smokers (OR 1.04, 95% CI 1.01-1.07, p=0.02). Ex-smokers were at significantly 
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higher risk of repeat antibiotic prescription compared to current smokers (OR 1.34, 95% 
CI 1.29-1.39, p<0.001). Not using amoxicillin as index antibiotic was associated with 
more repeat antibiotic prescriptions (OR 1.15, 95% CI 1.11-1.18, p<0.001). Seven day 
index courses were associated with more repeat prescriptions than both shorter and 
longer courses (OR 0.93, 95% CI 0.90-0.96, p<0.001; OR 0.86, 95% CI 0.79-0.94, 
p=0.001 respectively). Higher BMI was associated with further prescriptions (mean 
28.5±6.3 versus 28.1±6.7, MD -0.46, 95% CI -0.6 - -0.4, p<0.001). There was  no 
difference gender (p=0.08). 
[Table 1 here] 
Figure 1 shows that most repeat antibiotic prescriptions occurred following an 
index duration of 7 days. The proportion of cases receiving further antibiotics decreased 
with longer and shorter index duration. Fewer repeat prescriptions occurred when 
amoxicillin was used as index antibiotic. 
[Figure 1 here] 
Subgroup analysis for repeat LRTI code from 2011-2017  
89,694 cases were included in this period. The most commonly prescribed index duration 
was again 7 days (83.7%).The most frequently used index antibiotics were amoxicillin 
(70.3%), clarithromycin (14.7%) and co-amoxiclav (4.8%).  
Men were less likely to receive further antibiotics (OR 0.93, p=0.01, see 
supplementary table 2). Those receiving antibiotics were significantly older (mean age 
60 versus 57 years, p<0.001) with a higher BMI (29.0 versus 28.6, p<0.001). Current 
smokers were less likely to receive antibiotics (OR 0.81, 95% CI 0.76-0.87, p<0.001) 
than non-smokers, ex-smokers more likely than non-smokers (OR 1.05, 
95% CI 0.99-1.11, p=0.11) and significantly more likely than current smokers (OR 1.29, 
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95% CI 1.20-1.38, p<0.001). Not using amoxicillin as index antibiotic retained a higher 
risk of repeat prescription (OR 1.11, 95% CI 1.04-1.17, p<0.001). In contrast to the 
overall study findings shorter durations were now associated with a higher risk of repeat 
prescription than 7 day courses (OR 1.12, 95% CI 1.05-1.20, p=0.001). Longer durations 
maintained their lower risk of repeat antibiotics (OR 0.85, 95% CI 0.71-1.01, p=0.06).  
Further antibiotic prescription for any indication 
When considering all antibiotic prescriptions within 14 days of index prescription (41,227 
cases) clarithromycin, amoxicillin and doxycycline were used most commonly as second 
line agents (20.5%, 17.0% and 13.7%).  
Those receiving further courses were significantly older (mean 57.2 versus 
54.0 years, p<0.001) with a significantly higher BMI (mean 28.5 versus 28.1, p<0.001, 
see supplementary table 3). Men were significantly less likely to receive antibiotics than 
women (OR 0.93, 95% CI 0.91-0.95, p<0.001). Current smokers were less likely, ex-
smokers more likely to receive antibiotics than non-smokers (OR 0.79, 95% CI 0.77-0.82, 
p<0.001 and OR 1.04, 95% CI 1.01-1.07, p=0.002 respectively). Ex-smokers were 
significantly more likely to receive further antibiotics than current smokers (OR 1.31, 
95% CI 1.28-1.35, p<0.001). Not using amoxicillin as index drug was associated with 
higher risk of repeat antibiotics (OR 1.18, 95% CI 1.16-1.21, p<0.001; see figure 1b). 
Shorter index courses were associated with fewer repeat prescriptions than 7 day index 
courses (OR 0.94, 95% CI 0.91-0.96, p<0.001). There was no significant difference 
between longer and 7 day courses (OR 0.94, 95% CI 0.88-1.00, p=0.06). 
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Discussion 
We present a report of antibiotic prescribing for LRTI in over 525 primary care practices 
in the United Kingdom over 33 years. More than 365,000 truly representative, index 
prescriptions were analysed and more than one in twenty received two antibiotic courses 
for LRTI within 14 days. Our hypothesis-generating findings support the widespread use 
of amoxicillin as index drug and suggest that initial courses shorter than seven days could 
potentially be effective, as they were associated with a lower risk of repeat prescriptions. 
These findings should be confirmed in interventional studies. 
A key output from this study is a description of the frequency of and variation in 
prescribing practice for LRTI in primary care. Repeat antibiotic prescribing was common 
and in discrepancy to UK guidelines: the National Institute for Health and Care 
Excellence does not recommend routine antibiotic prescription for those presenting with 
likely self-limiting illnesses, including acute bronchitis, in primary care since in the 
majority of cases no pathogen or only respiratory viruses can be identified [8,9]. Yet 6.2% 
of our population even received two antibiotic courses for LRTI within two weeks. 
Treatment failure rates of 20% have been described previously but these included 
prescriptions for pneumonia and further antibiotics for all indications [10]. We present 
more specific data for LRTI, which can assist to plan future work. Most cases had only 
one index prescription, however, subgroup analysis of those with more index 
prescriptions showed no significant differences to the presented findings. 
Our findings were inconclusive regarding duration, highlighting the need for 
interventional research. Overall, shorter and longer courses than seven days seemed to be 
more successful at reducing the need for further antibiotics for LRTI. Shorter courses also 
had a lower risk for all repeat indications. However, shorter courses were associated with 
increased repeat prescriptions in the subgroup analysis from 2011-2017, whilst longer 
courses maintained their superiority over seven day courses. Yet for all indications there 
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was no difference between longer and seven day courses. With our data we are unable to 
establish whether this reflects changes in pathogens and disease or changes in presenting 
and prescribing behaviour by patients and clinicians. We did not have access to adverse 
effect data, which would be important for any future studies. A recent meta-analysis 
found an association of adverse effects and longer antibiotic duration in COPD patients 
[11].   
Repeat prescriptions were more common in older subjects, those with a higher 
BMI or previous smoking history. These findings appear to be clinically relevant and 
plausible as e.g. older patients are at higher risk of adverse outcomes from community 
acquired pneumonia [9]. Patients with previous smoking history are at risk of abnormal 
lung architecture, COPD and hence atypical bacterial infections [12]. Higher BMI may 
impair clearing of secretions but the mean difference in BMI was only 0.4 between groups 
which is unlikely to relate to clinical significance. Further work should be undertaken as 
these groups may have different needs for drugs and durations for LRTI due to co-
morbidities and different lung architecture. Amoxicillin treats Streptococcus 
pneumoniae, the most common bacterial cause of LRTI, hence our finding of fewer repeat 
prescriptions after initial amoxicillin therapy could be clinically plausible [9]. Whilst the 
effect sizes were small, LRTI are very common [9]. Hence even small differences of less 
than 1% could theoretically result in meaningful differences in antibiotic prescriptions 
due to the size of the population, if they were true. It may be worth exploring this in the 
future.  
Current smokers seemed to have a significantly reduced risk of repeat 
prescriptions (OR 0.78, 95% CI 0.75-0.81). Doctors may attribute cough in a current 
smoker to the smoking and hence not prescribe antibiotics. This is in contrast to 
retrospective European data where current smoking was an independent risk factor for 
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antibiotic prescription in primary care patients presenting with cough and the increased 
risk of community acquired pneumonia and death of pneumococcal disease in smokers  
[11–13]. Yet the cough study demonstrated no improved recovery with antibiotics and 
subgroup analysis of a multi-centre randomised, placebo-controlled trial of amoxicillin 
versus placebo in LRTI showed no clinically meaningful advantage of antibiotic 
treatment, supporting our described UK findings [14]. 
We analysed electronic health records. There is a drive to use more routinely 
collected data, particularly in primary care research, e.g. from the National Institute of 
Health Research, and highlighted by recent successes such as the Salford Lung Study, to 
reduce burden on patients, bias and approximate real-world practice [13,14]. However, 
the reliance on primary care data is also this study’s major limitation – specifically the 
49% of cases for which no index antibiotic duration was documented. The excluded cases 
had a lot of missing data (see supplementary table 4). The missing data had fewer non-
smokers (8.8%) but also more missing smoking data (26%). It is unclear whether this 
represents a true difference in prevalence of non-smoking or failure to code an absence 
of disease. We were unable to comment on the repeat prescriptions in the non-included 
group due to too much missing data. One may suspect that documentation improved over 
time with advancing information technology, however, from 2011 to 2017 there were 
206,455 cases in the database – and only 89,694 with a documented index duration (43%). 
More integrated healthcare technologies need to improve this in the future.  
Other limitations include lack of information on other healthcare contacts or signs 
of infection and on other confounders, e.g. non-respiratory co-morbidities, allergies, prior 
antibiotic use, unattainability of total number of LRTI in the study period and inability to 
distinguish appropriate from inappropriate prescribing. Yet treatment decisions are often 
made independent of these, e.g. initial clinical severity scores and clinical response to 
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therapy were not related to duration of antibiotic therapy in adults admitted with 
community acquired pneumonia [15]. Variations in clinical presentation did not explain 
the large discrepancies in antibiotic prescribing for acute cough in a cross-sectional study 
of 14 European countries [16]. Repeat prescriptions could have been issued due to 
genuine anti-microbial failure, but also due to drug failure caused by side effects or 
incorrect diagnoses. Better data is needed to distinguish these. 
Nevertheless, we present a hypothesis-generating real-world picture of the 
prescribing patterns of antibiotics for LRTI over 33 years in 7% of all UK primary care 
practices, analysing over 365,000 cases. With evidence on effective antibiotic treatment 
currently lacking it is paramount to have a historical, pragmatic perspective as a basis to 
design safe interventional studies in the future.  
 
Conclusion 
Antibiotics were prescribed for LRTI in people without chronic chest conditions. There 
was variation in practice and apparent deviation from guidelines. Amoxicillin as index 
drug seemed more successful in avoiding repeat antibiotic prescriptions than other agents, 
supporting the demonstrated current prescribing practice. The results for optimal 
antibiotic duration were less clear, but suggested that shorter index durations may be 
appropriate for LRTI. This pragmatic study has implications for further work 
around guideline implementation, antimicrobial resistance strategies, 
and interventional studies of antibiotic duration. 
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Tables with captions 
Table 1: Univariable analysis for repeat antibiotic prescription with LRTI code (total 
number 366,640) 
 Receiving second antibiotic 
course for LRTI 
 
Analysed 
variable 
Yes 
 
No 
 
Calculation p value 
Age (years) 57.5 ± 16.6 54.1 ± 17.7 MD -3.4 
(95% CI -3.6 - -3.1) 
< 0.001 
Smoking 
status 
    
Non-smoker 8,528 
(6.6%) 
121,363 
(93.4%) 
OR 1.00  
Current 
smoker 
5,135 
(5.2%) 
93,929 
(94.8%) 
OR 0.78 
(95% CI 0.75-0.81) 
< 0.001 
Ex-smoker 7,208 
(6.8%) 
98,737 
(93.2%) 
OR 1.04 
(95% CI 1.01 – 1.07) 
0.02 
Missing  
 
  n = 31,740  
Index drug     
Amoxicillin 13,905 
(5.8%) 
224,716 
(94.2%) 
OR 1.00  
Not 
amoxicillin 
7,323 
(6.6%) 
103,339 
(93.4%) 
OR 1.15 
(95% CI 1.11-1.18) 
< 0.001 
Missing 
 
  n = 17,357  
Index 
antibiotic 
duration 
    
7 days 16,732 
(6.2%) 
254,769 
(93.8%) 
OR 1.00  
< 7 days 4,904 
(5.8%) 
80,188 
(94.2%) 
OR 0.93 
(95% CI 0.90-0.96) 
< 0.001 
> 7 days 540 
(5.4%) 
9,507 
(94.6%) 
OR 0.86 
(95% CI 0.79-0.94) 
0.001 
BMI (kg/m2) 28.5 ± 6.3 28.1 ± 6.7 MD -0.46 
(95% CI -0.6 - -0.4) 
< 0.001 
Gender     
   Female 12957 
(6.1%) 
199,185 
(93.9%) 
1.00 0.08 
   Male 9219 
(6.0%) 
145,279 
(94.0%) 
OR 0.98 
(95% CI 0.95-1.00) 
 
(Mean ±  SD or absolute number + row % where appropriate; SD: standard deviation; 
OR: odds ratio; 95% CI: 95% Confidence interval; MD: mean difference; p value as per 
students T-test or Chi-Square) 
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Figure captions: 
Figure 1: Percentage of all prescriptions of specified index duration and index antibiotic 
receiving second antibiotic prescription for LRTI (a) or any indication (b) within 14 
days of index antibiotic prescription, by index duration and antibiotic group. (*p<0.005 
by Chi-square test) 
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Figure 1b
Supplementary data 
 
Total number of antibiotic prescriptions for 
LRTI in OPCRD from 1984-2017 
n = 1,549,402 
Prescriptions in “simple” LRTI 
n = 753,885 
Prescriptions with clearly documented index 
duration 
n = 367,188 
Clearly documented index prescriptions, with 
maximum one repeat prescription in 14 days 
n =366,640 
Prescriptions in cases with respiratory co-
morbidities or younger than 16 years 
n = 795,517 
Prescriptions without clearly documented index 
duration 
n = 386,697 
Second antibiotic prescription within 14 days of 
index prescription 
n = 41,227 
 
Second antibiotic prescription within 14 days of 
index prescription coded for LRTI 
n = 22,176 
2 repeat antibiotic prescriptions within 14 days 
of index prescription 
n = 548 
Supplementary Material - for review
Supplementary Figure 1 
Flowchart of cases included from the OPCRD  
 
Supplementary Table 1 
Supplementary Table 1: Baseline characteristics (total number 367,188) 
Characteristic N (%) or mean ± SD 
Gender  
Female 216,273 (58.9%) 
Male 150,915 (41.1%) 
Age 55.4 ± 18.0 
BMI 28.1 ± 6.1 
Smoking status  
Non-smoker 130,109 (35.4%) 
Current smoker 99,188 (27.0%) 
Ex-smoker 106,210 (28.9%) 
Missing 31,771 (8.7%) 
Number of index prescriptions per patient  
1 217,742 (59.3%)  
2 74,907 (20.4%)  
≥ 3  74,539 (20.3%) 
Year of index prescription#  
Earlier and up to 2000 60,324 (16.4%) 
2001-2005 87,532 (23.8%) 
2006-2010 129,463 (35.3%) 
Since 2011 89,869 (24.5%) 
Index duration  
≤ 4 days 1,704 (0.5%) 
5 and 6 days 83,477 (22.7%) 
7 days 271,955 (74.1%) 
8-10 days 7,188 (2.0%) 
≥ 11days  2,864 (0.7%) 
Index antibiotic  
Amoxicillin 238,948 (65.1%) 
Clarithromycin 33,307 (9.1%) 
Erythromycin 27,097 (7.4%) 
Co-amoxiclav 13,862 (3.8%) 
Cefalexin 12,573 (3.4%) 
Doxycycline 6,302 (1.7%) 
Cefaclor 6,274 (1.7%) 
Ciprofloxacin 6,087 (1.7%) 
Oxytetracycline 4,136 (1.1%) 
Ampicillin 1,218 (0.3%) 
Missing 17,384 (4.7%) 
(#one individual can be included in multiple periods) 
 
Supplementary Table 2 
Univariable analysis for repeat LRTI code from 2011-2017 (total number = 89,694) 
 Receiving second antibiotic 
course for LRTI 
 
Analysed 
variable 
Yes 
 
No 
 
Calculation p value 
Age (years) 60.3 ± 17.3 57.3 ± 18.5 Mean difference: -3.0 
(95 % CI -3.4 - -2.5) 
<0.001 
Smoking 
status 
    
Non-smoker 3,077 
(7.6 %) 
37,297 
(92.4 %) 
OR 1.00  
Current 
smoker 
1,301 
(6.3 %) 
19,359 
(93.7 %) 
0.81 
(95 % CI 0.76-0.87) 
< 0.001 
Ex-smoker 2,112 
(8.0 %) 
24,410 
(92.0 %) 
1.05 
(95 % CI 0.99-1.11) 
0.11 
Missing  
 
  2,138 
(2.4 %) 
 
Index drug    <0.001 
Amoxicillin 4,497 
(7.1 %) 
58,538 
(92.9 %) 
OR 1.00  
Not 
amoxicillin 
2,009 
(7.8 %) 
23,661 
(92.2 %) 
OR 1.11 
(95 % CI 1.04-1.17) 
 
Missing 
 
  989 
(1.1 %) 
 
Index 
antibiotic 
duration 
    
7 days 5,433 
(7.2 %) 
69,672 
(92.8 %) 
1.00  
< 7 days 994 
(8.1 %) 
11,352 
(91.9 %) 
1.12 
(95 % CI 1.05-1.20) 
0.001 
> 7 days 139 
(6.2 %) 
2,104 
(93.8 %) 
0.85 
(95 % CI 0.71-1.01) 
0.06 
BMI (kg/m2) 29.0 ± 6.5 28.6 ± 6.4 Mean difference: -0.4 
(95 % CI -0.6 - -0.3) 
<0.001 
Gender    0.009 
   Female 3,847 
(7.5 %) 
47,330 
(92.5 %) 
OR 1.00  
   Male 2,719 
(7.1 %) 
35,798 
(92.9 %) 
OR 0.93 
(95 % CI 0.89 – 0.98) 
 
 
Supplementary Table 3 
Univariable analysis for repeat antibiotic prescription for any indication within 14 days (total 
number = 366,640) 
 Receiving second antibiotic 
course for any indication 
 
Analysed 
variable 
Yes 
 
No 
 
Calculation p value 
Age (years) 57.2 ± 16.8 54.0 ± 17.7 Mean difference: -3.2 
(95 % CI  -3.4 - -3.1) 
<0.001 
Smoking 
status 
    
Non-smoker 15,418 
(11.9 %) 
114,473 
(88.1 %) 
OR 1.00  
Current 
smoker 
9,564 
(9.7 %) 
89,500 
(90.3 %) 
OR 0.79 
(95 % CI 0.77-0.82) 
< 0.001 
Ex-smoker 13,022 
(12.3 %) 
92,923 
(87.7 %) 
OR 1.04 
(95 % CI 1.01-1.07) 
0.002 
Missing  
 
  31,740 
(8.7 %) 
 
Index drug    <0.001 
Amoxicillin 25,536 
(10.7 %) 
213,085 
(89.3 %) 
OR 1.00  
Not 
amoxicillin 
13,752 
(12.4 %) 
96,910 
(87.6 %) 
OR 1.18 
(95 % CI 1.16-1.21) 
 
Missing 
 
  17,357 
(4.7 %) 
 
Index 
antibiotic 
duration 
    
7 days 30,977 
(11.4 %) 
240,524 
(88.6 %) 
OR 1.00  
< 7 days 9,164 
(10.8 %) 
75,928 
(89.2 %) 
OR 0.94, 
(95 % CI 0.91-0.96, 
< 0.001 
> 7 days 1,086 
(10.8 %) 
8,961 
(89.2 %) 
OR 0.94, 
(95 % CI 0.88-1.00, 
0.06 
BMI (kg/m2) 28.5 ± 6.3 28.1 ± 6.8 Mean difference: -0.4 
(95 % CI -0.5 - -0.3) 
<0.001 
Gender    <0.001 
   Female 24,510 
(11.6 %) 
187,632 
(88.4 %) 
OR 1.00  
   Male 16,717 
(10.8 %) 
137,781 
(89.2 %) 
OR 0.93 
(95 % CI 0.91-0.95) 
 
 
 
Supplementary table 4 
Comparison of characteristics of included and excluded patients based on documentation of 
index antibiotic duration 
Characteristic Included patients 
(n=367,188) 
N (%) or mean ± SD 
Excluded patients 
(n=386,697) 
N (%) or mean ± SD 
Gender   
Female 216,273 (58.9%) 213,244 (59.8%) 
Male 150,915 (41.1%) 173,453 (40.2%) 
Age 55.4 ± 18.0 56.3 ± 18.1 
BMI 28.1 ± 6.1 28.1 ± 6.3 
Smoking status   
Non-smoker 130,109 (35.4%) 34,029 (8.8%) 
Current smoker 99,188 (27.0%) 119,489 (30.9%) 
Ex-smoker 106,210 (28.9%) 132,637 (34.3%) 
Missing 31,771 (8.7%) 100,542 (26.0%) 
Number of index prescriptions 
per patient 
  
1 217,742 (59.3%)  110,209 (28.5%) 
2 74,907 (20.4%)  80,433 (20.8%) 
≥ 3  74,539 (20.3%) 196,055 (50.7%) 
Year of index prescription#   
Earlier and up to 2000 60,324 (16.4%) Not documented 
2001-2005 87,532 (23.8%) Not documented 
2006-2010 129,463 (35.3%) Not documented 
Since 2011 89,869 (24.5%) Not documented 
Index duration   
≤ 4 days 1,704 (0.5%) Not documented 
5 and 6 days 83,477 (22.7%) Not documented 
7 days 271,955 (74.1%) Not documented 
8-10 days 7,188 (2.0%) Not documented 
≥ 11days  2,864 (0.7%) Not documented 
Index antibiotic   
Amoxicillin 238,948 (65.1%) 235,498 (60.9%) 
Not amoxicillin  110,308 (30.2%)  132,250 (34.2%) 
Missing 17,384 (4.7%) 18,949 (4.9%) 
 
Repeat antibiotics for LRTI 
 
(n=366,640) 
 
Yes 22,176 (6.0%) Not documented 
No 345,012 (94.0%) Not documented 
 
Repeat antibiotics for all 
indications 
 
(n=366,640) 
 
Yes 41,227 (11.2%) Not documented 
No 325,961 (88.8%) Not documented 
Repeat antibiotics for LRTI 
code 2011-2017  
 
(n=89,694) 
 
Yes 6,566 (7.3%) Not documented 
No 83,128 (92.7%) Not documented 
 
